SOURCE: XTend Medical Corporation

October 22, 2009 08:30 ET

XTend Medical (XMDC) Updates Shareholders on Merger and Company's Progress

Management to Travel to Korea to Finalize Merger

SUN VALLEY, CA--(Marketwire - October 22, 2009) - XTend Medical (PINKSHEETS: XMDC), a company specializing in manufacturing and distributing the latest in telemedicine and diagnostic devices, released the following information regarding the company's progress on merger and company's progress:

"XTend would like to update our shareholders on our progress to date. Mr. Lee from BioHarp, Korea traveled to Los Angeles last weekend to meet with the executives of XTend. The meetings were very positive and included several aspects in the manufacturing process and the business model moving forward. I personally want to thank Mr. Lee for his dedication and efforts in moving the merger forward. The management of XTend will be traveling to Korea soon to meet with the executives of BioHarp, Korea to finalize the merger. We also intend to secure the manufacturing relationships Mr. Lee has worked on over the past months in order to fulfill our needs for the BioHarp unit. Mr. Lee has identified several major manufacturers that can handle the volume of devices we'll need to fulfill the commitments we expect over the next 6-12 months and having strategic manufacturing partners in Korea to work closely with the technical staff is imperative to the success of the company. While in Korea, XTend management will also be looking to secure a listing on the Korean Stock Exchange that will add to our shareholder base on a global basis and gain additional exposure for the company.

The combined efforts of the seasoned technical team in Korea with the management in the U.S. will insure that the BioHarp device will become the standard in medical diagnosis. Our intention is to market the product aggressively throughout Asia, the U.S. and Europe. To date, we've had over 7 inquiries from medical device companies looking to represent the BioHarp in 4 different countries globally. As we move forward, these opportunities will be explored and if they benefit the company, we will press forward on a working relationship.

As to the BioHarp unit itself, I would like to reiterate a few areas that make this device unique:

1. The BioHarp requires a pre-scan of the patient in order to get a baseline reading. This baseline reading is not based solely on a set of standards in the medical sector. These individualized baselines are established from the patient's own cellular makeup and further solidify how the BioHarp sets itself apart from any present of future competitors.

2. The BioHarp device is completely portable. Unlike CT Scanners and other large pieces of equipment that remain stationary, the BioHarp can travel to where the patients are. The unit is perfect for rural areas, battlefields, or other outlying areas that would benefit by having the BioHarp as part of their healthcare service.

3. BioHarp can be used to detect cellular inflammation in plants. Diseases in crops have risen dramatically over the years and the BioHarp can assist scientists in helping to determine the proper course of treatment in order to insure plants can sustain life. The global percussion in this area can be tremendous for the company.

4. The dedication Mr. Lee has spent on this device over the past 14 years is truly incredible. His vision for this device has proven instrumental in the development of the BioHarp. His technical staff has, and continues t, spend countless hours perfecting this product and we feel honored to become part of this exciting and truly unique product.

In closing, I would like to thank all of our shareholders for being patient as we close this merger. Mr. Lee and I have worked continuously over the past two years to insure you, as shareholders, will reap the benefits of being part of something we're very proud of. The future is very bright for this company and through hard work and dedication, the BioHarp will flourish and become the leading diagnostic device in the global medical community," stated Mr. Paul D. Lisenby, CEO of XTend Medical.

About XTend Medical

XTend Medical is a company that specializes in the manufacturing and distribution of the latest in telemedicine and telehealth solutions for the healthcare industry. Their dedication to insuring the products and services offered to healthcare organizations, third-world countries, and physician groups are at the forefront of medical technology. Their continued efforts in identifying global companies with true product potential in the healthcare industry puts them in an advantageous position to capitalize on a global basis. For further information, please contact them at

The new website can be located at

Forward-Looking Statements

This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets.

Contact Information